Bempedoic acid - Esperion Therapeutics
Alternative Names: ESP-55016; ETC-1002; NEXLETOL; NILEMDO; NilemdoLatest Information Update: 05 Jun 2024
At a glance
- Originator Esperion Therapeutics
- Developer Daiichi Sankyo Europe; Esperion Therapeutics; Otsuka Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dyslipidaemias; Hypercholesterolaemia
- Registered Cardiovascular disorders
- Phase I Hypertension
Most Recent Events
- 29 May 2024 Adverse events and efficacy data from the phase-III CLEAR Outcomes trial in Cardiovascular disorders released by Daiichi Sankyo Company
- 22 May 2024 Registered for Cardiovascular disorders (Treatment-experienced) in European Union, Iceland, Norway, Liechtenstein (PO)
- 06 Apr 2024 Adverse events and efficacy data from the phase-III CLEAR Outcomes trial in Cardiovascular disorders presented at the 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)